Loading clinical trials...
Loading clinical trials...
A Two-part, Randomized, Double-blind, Single-dose, Crossover Study to Compare Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Adult Volunteers
Conditions
Interventions
Daprodustat
Locations
4
United States
GSK Investigational Site
Anaheim, California, United States
GSK Investigational Site
Overland Park, Kansas, United States
GSK Investigational Site
Las Vegas, Nevada, United States
GSK Investigational Site
Austin, Texas, United States
Start Date
December 18, 2020
Primary Completion Date
May 18, 2021
Completion Date
May 18, 2021
Last Updated
April 10, 2025
NCT06884280
NCT06601712
NCT07082205
NCT07010237
NCT05251493
NCT07340450
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions